Y-Intercept (HK)
TRAX icon

Y-Intercept (HK)’s First Tracks Biotherapeutics TRAX Stock Holding History

Y-Intercept (HK)’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-28,084
Closed -$565K – 2238
2026
Q2 		$565K Buy
+28,084
New +$525K 0.01% 1280

Other funds holding TRAX

Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Adirondack Trust Company
Adirondack Trust Company Saratoga Springs, New York $320M AUM 23.25% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Y-Intercept (HK)'s TRAX Position: Q3 2026 in Review

Y-Intercept (HK) sold out of First Tracks Biotherapeutics (TRAX) in Q3 2026, closing a stake of 28,084 shares — an estimated $565K sold.

Y-Intercept (HK) first reported a position in TRAX in Q2 2026 and held it in 1 quarter. The position peaked at $565K in Q2 2026. 12 funds tracked by Wall St. Rank hold TRAX as of Q3 2026.

  • Y-Intercept (HK) reported no remaining First Tracks Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 28,084 First Tracks Biotherapeutics shares in Q3 2026, an estimated $565K.
  • Y-Intercept (HK) first reported a position in First Tracks Biotherapeutics in Q2 2026 and held it in 1 quarter.
  • Y-Intercept (HK)'s First Tracks Biotherapeutics position peaked at $565K in Q2 2026.
  • 12 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.